{"id":63048,"date":"2026-05-04T01:02:22","date_gmt":"2026-05-03T23:02:22","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-vistas-study-of-volixibat-in-patients-with-primary-sclerosing-cholangitis-on-may-4-2026\/"},"modified":"2026-05-04T01:02:22","modified_gmt":"2026-05-03T23:02:22","slug":"mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-vistas-study-of-volixibat-in-patients-with-primary-sclerosing-cholangitis-on-may-4-2026","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-vistas-study-of-volixibat-in-patients-with-primary-sclerosing-cholangitis-on-may-4-2026\/","title":{"rendered":"Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026"},"content":{"rendered":"
\n

FOSTER CITY, Calif.–(BUSINESS WIRE)–Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will host an investor call on Monday, May 4, 2026 at 8:30 a.m. ET\/5:30 a.m. PT to share topline results from the VISTAS study of volixibat in patients with primary sclerosing cholangitis (PSC).<\/p>\n

<\/a>
<\/a><\/p>\n

\nConference Call Details:<\/b><\/p>\n

\nUS\/Toll-Free: + 1 833 461 5787
\n
International: +1 585 542 9983
\n
Access Code: 151345102<\/p>\n

\nYou may also access the call via webcast by visiting the Investors<\/a> section of Mirum\u2019s corporate website. The archived webcast will be available for replay.<\/p>\n

\nAbout Mirum Pharmaceuticals<\/b><\/p>\n

\nMirum Pharmaceuticals (NASDAQ: MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum combines deep rare disease expertise with strong connections to patient communities.<\/p>\n

\nThe company\u2019s commercial portfolio includes LIVMARLI\u00ae<\/sup> (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM\u00ae<\/sup> (cholic acid) for bile-acid synthesis disorders, and CTEXLI\u00ae<\/sup> (chenodiol) for cerebrotendinous xanthomatosis (CTX).<\/p>\n

\nMirum\u2019s clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV) and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS).<\/p>\n

\nMirum\u2019s success is driven by a team dedicated to advancing high impact medicines through strategic development, disciplined execution and purposeful collaboration across the rare disease ecosystem. Learn more at www.mirumpharma.com<\/a> and follow Mirum on Facebook<\/a>, LinkedIn<\/a>, Instagram<\/a> and X<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Contact:<\/b>
Andrew McKibben
\n
ir@mirumpharma.com<\/a><\/p>\n

\nMedia Contact:<\/b>
Meredith Kiernan
\n
media@mirumpharma.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

FOSTER CITY, Calif.–(BUSINESS WIRE)–Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will host an investor call on Monday, May 4, 2026 at 8:30 a.m. ET\/5:30 a.m. PT to share topline results from the VISTAS study of volixibat in patients with primary sclerosing cholangitis (PSC). Conference Call Details: US\/Toll-Free: + … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-63048","6":"format-standard","7":"category-industry"},"yoast_head":"\nMirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-vistas-study-of-volixibat-in-patients-with-primary-sclerosing-cholangitis-on-may-4-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"FOSTER CITY, Calif.–(BUSINESS WIRE)–Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will host an investor call on Monday, May 4, 2026 at 8:30 a.m. ET\/5:30 a.m. PT to share topline results from the VISTAS study of volixibat in patients with primary sclerosing cholangitis (PSC). Conference Call Details: US\/Toll-Free: + ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-vistas-study-of-volixibat-in-patients-with-primary-sclerosing-cholangitis-on-may-4-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-03T23:02:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260503644332\/en\/746217\/22\/Mirum_Inline_FullColor_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-vistas-study-of-volixibat-in-patients-with-primary-sclerosing-cholangitis-on-may-4-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-vistas-study-of-volixibat-in-patients-with-primary-sclerosing-cholangitis-on-may-4-2026\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026\",\"datePublished\":\"2026-05-03T23:02:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-vistas-study-of-volixibat-in-patients-with-primary-sclerosing-cholangitis-on-may-4-2026\\\/\"},\"wordCount\":299,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-vistas-study-of-volixibat-in-patients-with-primary-sclerosing-cholangitis-on-may-4-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260503644332\\\/en\\\/746217\\\/22\\\/Mirum_Inline_FullColor_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-vistas-study-of-volixibat-in-patients-with-primary-sclerosing-cholangitis-on-may-4-2026\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-vistas-study-of-volixibat-in-patients-with-primary-sclerosing-cholangitis-on-may-4-2026\\\/\",\"name\":\"Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-vistas-study-of-volixibat-in-patients-with-primary-sclerosing-cholangitis-on-may-4-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-vistas-study-of-volixibat-in-patients-with-primary-sclerosing-cholangitis-on-may-4-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260503644332\\\/en\\\/746217\\\/22\\\/Mirum_Inline_FullColor_RGB.jpg\",\"datePublished\":\"2026-05-03T23:02:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-vistas-study-of-volixibat-in-patients-with-primary-sclerosing-cholangitis-on-may-4-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-vistas-study-of-volixibat-in-patients-with-primary-sclerosing-cholangitis-on-may-4-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-vistas-study-of-volixibat-in-patients-with-primary-sclerosing-cholangitis-on-may-4-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260503644332\\\/en\\\/746217\\\/22\\\/Mirum_Inline_FullColor_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260503644332\\\/en\\\/746217\\\/22\\\/Mirum_Inline_FullColor_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-vistas-study-of-volixibat-in-patients-with-primary-sclerosing-cholangitis-on-may-4-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-vistas-study-of-volixibat-in-patients-with-primary-sclerosing-cholangitis-on-may-4-2026\/","og_locale":"en_US","og_type":"article","og_title":"Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026 - Pharma Trend","og_description":"FOSTER CITY, Calif.–(BUSINESS WIRE)–Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will host an investor call on Monday, May 4, 2026 at 8:30 a.m. ET\/5:30 a.m. PT to share topline results from the VISTAS study of volixibat in patients with primary sclerosing cholangitis (PSC). Conference Call Details: US\/Toll-Free: + ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-vistas-study-of-volixibat-in-patients-with-primary-sclerosing-cholangitis-on-may-4-2026\/","og_site_name":"Pharma Trend","article_published_time":"2026-05-03T23:02:22+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260503644332\/en\/746217\/22\/Mirum_Inline_FullColor_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-vistas-study-of-volixibat-in-patients-with-primary-sclerosing-cholangitis-on-may-4-2026\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-vistas-study-of-volixibat-in-patients-with-primary-sclerosing-cholangitis-on-may-4-2026\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026","datePublished":"2026-05-03T23:02:22+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-vistas-study-of-volixibat-in-patients-with-primary-sclerosing-cholangitis-on-may-4-2026\/"},"wordCount":299,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-vistas-study-of-volixibat-in-patients-with-primary-sclerosing-cholangitis-on-may-4-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260503644332\/en\/746217\/22\/Mirum_Inline_FullColor_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-vistas-study-of-volixibat-in-patients-with-primary-sclerosing-cholangitis-on-may-4-2026\/","url":"https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-vistas-study-of-volixibat-in-patients-with-primary-sclerosing-cholangitis-on-may-4-2026\/","name":"Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-vistas-study-of-volixibat-in-patients-with-primary-sclerosing-cholangitis-on-may-4-2026\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-vistas-study-of-volixibat-in-patients-with-primary-sclerosing-cholangitis-on-may-4-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260503644332\/en\/746217\/22\/Mirum_Inline_FullColor_RGB.jpg","datePublished":"2026-05-03T23:02:22+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-vistas-study-of-volixibat-in-patients-with-primary-sclerosing-cholangitis-on-may-4-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-vistas-study-of-volixibat-in-patients-with-primary-sclerosing-cholangitis-on-may-4-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-vistas-study-of-volixibat-in-patients-with-primary-sclerosing-cholangitis-on-may-4-2026\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260503644332\/en\/746217\/22\/Mirum_Inline_FullColor_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260503644332\/en\/746217\/22\/Mirum_Inline_FullColor_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-vistas-study-of-volixibat-in-patients-with-primary-sclerosing-cholangitis-on-may-4-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/63048","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=63048"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/63048\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=63048"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=63048"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=63048"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}